Raphi Levy Sells 32,500 Shares of Alpha Tau Medical (NASDAQ:DRTS) Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 32,500 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $10.83, for a total value of $351,975.00. Following the completion of the sale, the chief financial officer owned 147,680 shares in the company, valued at approximately $1,599,374.40. This trade represents a 18.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Alpha Tau Medical Stock Performance

DRTS stock traded down $0.32 during midday trading on Thursday, reaching $10.26. 1,152,083 shares of the company were exchanged, compared to its average volume of 537,906. Alpha Tau Medical Ltd. has a one year low of $2.81 and a one year high of $11.62. The firm has a market capitalization of $926.79 million, a price-to-earnings ratio of -15.33 and a beta of 1.19. The business has a 50-day moving average price of $8.48 and a two-hundred day moving average price of $6.92. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79.

Alpha Tau Medical (NASDAQ:DRTS) last issued its quarterly earnings data on Monday, May 18th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.13). Equities research analysts forecast that Alpha Tau Medical Ltd. will post -0.6 EPS for the current year.

Wall Street Analyst Weigh In

DRTS has been the subject of a number of recent analyst reports. LADENBURG THALM/SH SH upped their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Citigroup upped their price target on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Barclays increased their price target on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday. Zacks Research upgraded Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. Finally, Piper Sandler lifted their price target on Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research note on Tuesday, May 19th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $12.60.

Hedge Funds Weigh In On Alpha Tau Medical

Several large investors have recently modified their holdings of DRTS. Apella Capital LLC bought a new position in Alpha Tau Medical in the fourth quarter worth approximately $1,892,000. Daytona Street Capital LLC acquired a new stake in Alpha Tau Medical in the 4th quarter valued at $749,000. Mariner LLC increased its stake in Alpha Tau Medical by 185.8% during the 3rd quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after purchasing an additional 80,129 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Alpha Tau Medical by 185.7% in the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock valued at $534,000 after buying an additional 70,081 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Alpha Tau Medical during the first quarter valued at about $286,000. Institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.